2026-11-15 · 2026-11 / week-3

Solésence's Q3 rebound is real; its inventory controls remain unproven

Solésence's Q3 rebound is real; its inventory controls remain unproven

Summary: Solésence reported $20.2 million of Q3 revenue, gross margin of 39.3%, and $3.67 million of net income. The stock then rose 67.22% to $1.52. Yet nine-month revenue fell 2.3% year over year and nine-month net income was nearly unchanged. The Q3 10-Q also records a $3.63 million inventory restatement, two material weaknesses, a capped lender waiver tied to inventory over-advances, and 68% of Q3 revenue from three customers. The better quarter may mark a real operating turn, but the new quote has no evidenced +10% base or bounded downside. Reject / no trade.

Opportunity Ranking

This ranks fresh U.S.-long research candidates by the quality of the disagreement, not by the size of the day's move. SPY is the liquid broad-market control: it closed at $754.37 on Nov. 13, down 0.36%.

Rank Candidate Direction Mispricing Evidence Freshness Catalyst Window Positioning 10/5 Status Tradeability Main Rejection Risk
1 Solésence (SLSN) Long Record Q3 profit and margin versus flat nine-month sales, concentrated customers, and inventory-costing control failures Nov. 12 Q3 10-Q/release; Nov. 13 close Post-results price acceptance; no new dated issuer catalyst verified within 20 sessions 17.57M shares traded, about 24.9% of Nov. 12 outstanding shares; current owners and short interest unknown Reject: flat base, credible adverse move about 40%, no downside bound Nasdaq common stock; live spread, depth and exit capacity unverified Inventory restatement, material weaknesses, customer concentration and related-party credit exposure
2 Ameresco (AMRC) Long $7.15B project backlog against $2.59B contracted; Q3 cash flow was negative before federal project proceeds Nov. 9 Q3 10-Q/release; Nov. 13 close Contract signing and conversion of awarded projects Current ownership, short and options positioning not checked Reject: no evidenced +10% base or bounded adverse case NYSE common stock; execution quality not checked Awarded backlog is unsigned; asset debt and cash conversion remain central
3 Wolverine World Wide (WWW) Long Q3 revenue rose 7.5% and guidance increased, but the share price reached its 52-week high after an 8.83% result-day gain Nov. 12 Q3 release; Nov. 13 close Holiday sales and final FY26 reporting; no nearer dated catalyst identified Current flows and options positioning not checked Reject: no evidenced price gap after the result-day move NYSE common stock; live exit data not checked Consumer demand, tariff refunds and seasonal mix may not repeat

Selected opportunity: SLSN as the most informative no-trade screen, not the best executable long.

Why this one now: The Nov. 12 filing confirms a sharp Q3 improvement and also gives the details behind the inventory correction and lender waiver. The market's 67% next-session gain makes the disagreement observable. The question is whether one quarter establishes a durable per-share earnings base after the restatement and debt-covenant issue.

Archive boundary: No SLSN or AMRC article or signal exists. WWW appeared only as a Q2 comparison in an August screen. This comparison uses Wolverine's new Q3 results and raised FY26 outlook, not the earlier inventory-and-debt comparison.

What should surprise the reader: Revenue increased 38% in Q3, but nine-month revenue was 2.3% lower than the prior year. The company also says the restatement did not change actual cash receipts or payments. The concern is the borrowing-base and reporting-control boundary, not a claim that cash vanished.

Why This Is the Best Opportunity Right Now

SLSN has a measurable price response to fresh operating evidence and a filing that qualifies the headline. The record Q3 result is meaningful: reported revenue, gross margin and net income all improved. But the quarter follows two loss-making quarters, while the nine-month sales and net-income totals were both slightly below the prior-year period. Inventory controls are still a reported material weakness, and the inventory revolver is held by a related party.

AMRC's Q3 showed strong earnings and a large backlog, but more than $4.5 billion of its reported project backlog remained awarded and unsigned. Its Q3 operating cash flow was negative before $12.6 million of federal ESPC proceeds. WWW's Q3 and guidance were strong, but the 8.83% result-day gain left it near its 52-week high. SLSN ranks first for its specific earnings-quality and collateral test, not because a 67% rally is attractive.

Why It Could Move More Than 5% Soon

StockAnalysis/S&P Global reports SLSN rose 67.22% to $1.52 on Nov. 13, with a $1.02-$1.86 range and 17,567,147 shares traded. The results were issued after the Nov. 12 close. The move clears the greater-than-5% discovery filter; it does not show that the new level is fair value.

A reversal to the Nov. 12 close of $0.91 would be a 40.1% decline from $1.52. That is a reference scenario, not a forecast or a floor. No later issuer event with a verified date was found inside the next 20 sessions. The next useful tests are repeat margins, customer orders and evidence that the inventory-costing controls operate as designed.

10/5 Asymmetry Gate

The reference-only 20-session map uses the Nov. 13 high, close and the Nov. 12 pre-result close. The highest-probability base is unchanged at $1.52, not +10%. The downside marker is about 40% below the quote, and losses below it remain possible. The stock's event-day turnover does not establish exit capacity.

10/5 status: Reject / no trade. The base misses +10%, credible adverse risk exceeds -5%, the base-to-adverse ratio is 0:1, and no net expected value after costs can be established.

The Setup

Fact: The Nov. 12 Q3 release reports revenue of $20.163 million, versus $14.597 million a year earlier; gross profit was $7.928 million, versus $3.474 million; and net income was $3.670 million, versus a $1.016 million loss. Gross margin rose to 39.3% from 23.8%. The issuer calls it its highest Q3 revenue and net income to date.

Fact: Nine-month revenue was $48.453 million, down 2.3% from $49.581 million. Nine-month net income was $2.478 million, compared with $2.536 million. Q1 and Q2 net losses totaled $1.192 million before Q3's $3.670 million profit. That makes the latest quarter a real change in reported results, but not yet proof of a stable annual run rate.

Fact: Nine-month cash from operations was $8.427 million, but the filing says the main drivers were net income, lower inventory and customer prepayments. Investing cash use was $1.535 million; financing cash use was $6.910 million, primarily for related-party debt reduction. Cash at Sept. 30 was $1.270 million. The positive operating cash flow is real, but inventory reduction and advance payments may not recur at the same rate.

Fact: The Q3 10-Q restates inventory downward by $3.632 million at Dec. 31, 2025, reducing previously reported total assets from $50.055 million to $46.423 million. The filing says the restatement did not change actual cash receipts or payments. It describes material weaknesses in inventory costing and financial-reporting oversight that existed at Sept. 30; correction of the historical figures alone does not remediate those weaknesses.

Fact: The filing says the inventory errors would have caused an over-advance default under the related-party inventory revolving loan effective Aug. 17. Beachcorp waived defaults from over-advances up to $3.0 million per occurrence. The company says it expects no prospective impact on availability, but the filing does not quantify each over-advance. The inventory line balance was $6.3 million at Sept. 30; the receivables line was $1.029 million and related-party term debt was $1.0 million.

Fact: The three largest customers represented 68% of Q3 revenue and 65% of nine-month revenue. Customer No. 1 alone was 51% of Q3 sales and 49% year to date. Receivables from those three customers totaled $6.836 million at Sept. 30. This concentration makes a single quarter less informative about repeatability.

Fact: Solésence reported 70,647,045 common shares outstanding on Nov. 12. At the Nov. 13 close, that gives an approximate basic equity-value proxy of $107.4 million. It is not fully diluted market capitalization or enterprise value.

Inference: The Q3 margin and profit step-up may persist as volume and efficiency improve. The opposing case is that the quarter follows two losses, the three largest customers drive 68% of sales, and the inventory accounting that underpins related-party collateral was not controlled well enough to avoid restatements and a waiver.

The Market Price

StockAnalysis, citing S&P Global Market Intelligence reports SLSN at $1.52 at the Nov. 13, 2026 regular close, up $0.61 or 67.22%, with a $1.02-$1.86 range and 17,567,147 shares traded. Compared with the 70,647,045 shares outstanding on Nov. 12, event-day volume was about 24.9% of shares outstanding. That is turnover, not a measurement of net new owners or sustainable liquidity.

The approximately $107.4 million basic equity-value proxy is about 43 times nine-month net income. If Q3 net income were simply annualized, the multiple would be about 7.3 times. Neither is an earnings forecast or fair-value estimate; the difference shows that the valuation depends on whether Q3 is a new run rate or a seasonal outlier. No independent analyst consensus or current valuation model was verified.

The Mispricing

The bullish interpretation is that Q3 marks an operating inflection: revenue and gross margin rose, net income turned positive, the nine-month cash-flow statement shows $8.427 million from operations, and the company reduced related-party debt. If the new volume and margin levels persist, the market may be applying too much weight to earlier losses and the inventory correction.

The countercase is that nine-month sales and net income remain near or below the prior year, 68% of Q3 revenue came from three customers, and Q3 cash from operations depended partly on inventory decline and customer deposits. Inventory had been overstated in prior reports. The material weaknesses remained at Sept. 30, and an inventory-based lender had waived a borrowing-base default. The market may be treating a strong quarter as durable before controls, customer breadth and lending compliance are demonstrated.

I do not have sufficient reliable data to quantify the market-implied probability that Q3 margins persist. The 67% price reaction is observed; the market's forecast is not.

The Positioning

Observed: SLSN traded 17.57 million shares on Nov. 13, versus 1.67 million the prior session, while the close rose 67.22%. That is about 10.5 times prior-session volume and about 24.9% of common shares outstanding.

Unknown: Current holder concentration, short interest, borrow, options, dealer exposure, institutional flows, spread, depth, venue quality, volume quality and realistic exit capacity were not verified. A large one-day turnover figure does not prove durable liquidity or accumulation. Positioning score: 2/5.

The Catalyst

Event Timing Test
Q3 operating result Reported Nov. 12; first regular-session reaction Nov. 13 Track whether revenue and gross margin persist without another inventory release or unusual customer prepayment.
Inventory-costing remediation No completion date verified Require controls to operate for a sustained period and management to conclude they are effective; a corrected statement alone is insufficient.
Inventory-facility borrowing base Related-party waiver effective Aug. 17, capped at $3.0M per over-advance occurrence Verify eligible inventory, outstanding advances, compliance certificate and any new waiver or cure. The company says it expects no prospective impact.
Customer concentration Next quarterly disclosure; no date verified Track repeat orders, receivables collection and revenue shares for the three largest customers.

There is no dated issuer catalyst verified inside the 20-session window after the Q3 report. The cheap disconfirming sequence is the next filing: inspect inventory costing, gross margin, customer concentration and cash conversion before assigning a new earnings multiple.

The Payoff

The strongest long path is that the Q3 gross-margin improvement continues, working-capital needs remain manageable and the largest consumer-product customers repeat orders. The nine-month operating cash result and debt reduction support that case. A higher multiple on sustained earnings could support further gains.

The downside case is a reversion toward the pre-result close if the quarter fails to repeat, with additional risk if a lender questions collateral value, customers reduce purchases or the stock's thin normal-session volume returns. The material weaknesses and restatement raise forecast uncertainty; they do not prove fraud or a cash loss. A high Q3 result can be real and still be a poor entry after a 67% gap.

Price Target and Probability Map

Reference-only 20-session map through Dec. 14, 2026. The top is the Nov. 13 intraday high, the base is the Nov. 13 close, and the bottom is the Nov. 12 pre-result close. These are observed market markers, not fair-value targets or downside bounds. Probabilities are subjective judgments, not observed frequencies. The base receives the highest weight because no dated issuer event was found in the window; the lower-weight top and bottom scenarios depend on whether the Q3 profit step-up persists or fades.

Scenario Probability Target / Level Return / Payoff Horizon Conditions Evidence Quality
Top Case 15% $1.86 +22.4% Through Dec. 14, 2026 The market retests the Nov. 13 high if the Q3 margin and profit are treated as a continuing run rate Low
Base Case 60% $1.52 0.0% Same Investors wait for a second quarter of results and proof of inventory-control remediation Low
Bottom Case 25% $0.91 -40.1% Same The event gap retraces to the Nov. 12 close as customer concentration or inventory-lending questions dominate; losses below remain possible Low
Invalidation n/a A subsequent filing shows repeated profitable quarters, effective inventory controls, stable customer concentration, collected receivables and no borrowing-base over-advances No position exists to invalidate Before reconsideration Medium

Probability-weighted price marker: $1.42, or -6.7% gross from the Nov. 13 close before costs. This is not a net expected value; the markers are not fundamental targets and the bottom is not a loss boundary.

Sensitivity: If the bottom marker is limited to the Nov. 13 session low of $1.02 with the same 15% / 60% / 25% weights, the weighted marker is about $1.45, or -4.9%. With the original $0.91 bottom but a more optimistic 25% / 55% / 20% weighting, the weighted marker is about $1.48, or -2.4%. Neither sensitivity creates a +10% base or bounds downside below 5%.

Current market level and timestamp: $1.52 at the Nov. 13, 2026 regular-session close, 4:00 p.m. EST.

Primary instrument: SLSN common stock, unlevered.

10/5 favorable base move: 0.0% from the reference close.

10/5 credible adverse move: At least 40.1% to the pre-result close; losses below that mark are not bounded.

10/5 measurement basis: Reference-only; no verified executable entry.

10/5 status: Reject / no trade.

Confidence: Low. The headline operating improvement is verified, but the forward earnings and borrowing-base bridges remain unresolved.

The Kill Shot

The best counterargument is that this is a genuine operating improvement, not an accounting-only gain. Solésence reported $3.67 million of Q3 net income, 39.3% gross margin and $8.43 million of nine-month operating cash. The inventory restatement did not change actual cash receipts or payments. The inventory facility lender waived specified over-advances, and the company says it expects no prospective impact on the facility. If the next quarter sustains the higher gross margin and converts sales to cash, the Q3 print could be an inflection.

The main concern is the operating and accounting denominator. Nine-month sales were still down 2.3%, three customers made up 68% of Q3 revenue, and management identified inventory-costing and financial-review weaknesses as of Sept. 30. The positive nine-month cash flow relied partly on inventory reduction and customer prepayments; those sources can reverse.

Load-bearing assumption: The Q3 gross margin and customer demand persist without new inventory over-advances or another material correction.

What Could Go Wrong

  • A top customer reduces or delays orders, changing a large share of revenue at once.
  • The Q3 margin reverts as product mix, labor and manufacturing overhead costs normalize.
  • Inventory adjustments, obsolescence or borrowing-base recertification reduce eligible collateral.
  • The related-party lender declines new over-advances or requires paydown despite the current waiver.
  • Customer prepayments or inventory liquidation made nine-month operating cash look stronger than repeat cash conversion.
  • A further correction, disclosure delay or weak control remediation reduces confidence in reported earnings.
  • The post-gap share price gives back part of the move; low-depth trading, halts or gaps can extend losses beyond the observed $0.91 marker.

What Would Prove This Wrong

A new filing that shows two or more quarters of profitable growth, gross-margin stability, collected receivables, inventory controls that have operated and been tested, and an inventory facility within its borrowing base would weaken this Reject. The cheapest test is to reconcile those items to the next 10-Q rather than annualize one quarter.

Risk Audit

  • Earnings: Q3 net income was $3.670 million, but nine-month net income was $2.478 million versus $2.536 million a year earlier. Q3 is the inflection to test, not a validated run rate.
  • Revenue: Nine-month sales declined 2.3%; three customers made up 68% of Q3 revenue.
  • Inventory: The 2025 restatement reduced December inventory by $3.632 million. The filing says no cash flows changed, but inventory-costing and financial-review weaknesses remained as of Sept. 30.
  • Credit: The inventory line balance was $6.3 million and the receivables line was $1.029 million, both related party. The $3.0 million waiver cap per over-advance occurrence is specific and does not establish future facility availability.
  • Cash: Cash was $1.270 million at Sept. 30. Nine-month operating cash flow was positive, but largely reflected income, lower inventory and customer prepayments; financing cash was used to repay debt.
  • Execution: Market data uses the Nov. 13 regular close. Current spread, depth, venue, volume quality and exit capacity are unknown. No market order, options or leverage case is modeled.

Best Trade Strategy

No trade. The only simple expression is unlevered SLSN common stock, but the base case is flat, the downside marker is 40.1% below the close and no loss bound is supported. Keep entry.price null and execution.can_execute false. Reconsider only after the next filing establishes sustained cash earnings, effective inventory controls, and a borrowing base that reconciles to eligible stock.

Sources

  1. Solésence Q3 2026 Form 10-Q, filed Nov. 12, 2026.
  2. Solésence Q3 2026 results release, Nov. 12, 2026.
  3. Solésence Q2 2026 Form 10-Q/A, filed Nov. 10, 2026.
  4. SLSN Nov. 13 regular close and volume, citing S&P Global Market Intelligence.
  5. Ameresco Q3 2026 results, Nov. 9, 2026, and Form 10-Q.
  6. AMRC Nov. 13 regular close and volume, citing S&P Global Market Intelligence.
  7. Wolverine Q3 2026 results, Nov. 12, 2026.
  8. WWW Nov. 13 regular close and volume, citing S&P Global Market Intelligence.
  9. SPY Nov. 13 close and volume, citing S&P Global Market Intelligence.

Research Quality Scorecard

Criterion Score Evidence
Market disagreement 4/5 Record Q3 growth versus flat nine-month sales, customer concentration and inventory-costing control failures
Evidence base 4/5 Fresh Q3 filing, corrected statements and market reference; repeatability remains untested
Positioning and flows 2/5 Event-day turnover is observed, but holder, short, option and exit data are missing
Catalyst path 3/5 Q3 is reported; next proof points are monitorable but not dated inside the window
Payoff architecture 3/5 Reference map and sensitivity are explicit; neither provides a fair-value floor
Invalidation discipline 4/5 Next report, customer mix, controls and borrowing base provide clear tests
Differentiated insight 5/5 Connects inventory-costing restatement to borrowing-base risk and cash conversion
Client value 4/5 Separates a real earnings rebound from a tradeable common-equity setup

Total: 29/40. The screen is useful research; the failed 10/5 economics require Reject / no trade.

Bottom Line

Solésence had a strong quarter: sales grew, gross margin improved, and the company reported positive net income and operating cash. But nine-month sales were down, customer concentration rose, the inventory restatement reached the borrowing base, and two material weaknesses remained. A 67% price gap may be a fair response to a real improvement, but this screen cannot show a +10% base or cap downside at 5%. Reject / no trade.

AI Illustration Prompt

An editorial view across a small cosmetic-ingredient factory and a financial ledger: one production line of zinc-oxide sunscreen ingredients runs cleanly at the front, while an inventory ledger in the foreground has two stamped columns, “reported” and “restated,” beside an inventory-loan borrowing-base certificate with a waiver cap and a list of three customer accounts totaling 68%; include a cash-flow panel showing “$8.4M operating cash, nine months” with smaller notes “inventory decrease” and “customer prepayments”; place a stock-price band from “$0.91 pre-result” to “$1.52 close” as a narrow caption, not a chart; restrained paper white, charcoal, warm sand and muted blue; no cosmetic brand logos, no trading screen, no guaranteed return, and a subtle readable “The Mispricing Desk” watermark at lower right.